Clarivate

Global Pharma And AI Trends Will Build Future Growth

AnalystConsensusTarget

Not Invested

Based on Analyst Price Targets

Published

11 May 25

Updated

24 Nov 25

n/a

AnalystConsensusTarget's Fair Value

n/a

-34.4%

10.6%

-34.4%

10.6%

You can edit this narrative until Nov 25 7:10 AM. Then, changes will post as Updates.

Author's Valuation

US$4.9325.8% undervalued

AnalystConsensusTarget Fair Value

Narrative

Updates2

Shared on 24 Nov 25

CLVT: Strong Market Share Will Support Future Performance Despite AI Risk

Analysts have slightly raised their price target for Clarivate to nearly $5 per share. They cite the firm’s solid market position but note ongoing risks from budget constraints, AI competition, and leverage concerns.

Shared on 09 Nov 25

Fair value Decreased 4.14%

CLVT: Market Position And AI Developments Will Drive Performance Ahead

Analysts have lowered Clarivate's price target from approximately $5.14 to $4.93 per share. They cite concerns over budget constraints in key sectors, potential risks from artificial intelligence, and the company’s elevated leverage, despite its strong market position.

AnalystConsensusTarget Fair Value

US$4.93

25.8% undervalued

Future estimation in

% p.a.

Decrease

Increase

Current revenue growth rate

0.10%

Professional Services revenue growth rate

0.22%

Risk Level (Discount Rate)

Our default considers factors like the company's size, volatility, profitablity and country of operation.

Decrease

Increase

Current discount rate

11.70%

Calculation

US$41.64m

Earnings '28

95.49x

PE Ratio '28

US$3.98b

Market Cap '28

US$3.98b

Market Cap '28

578.51m

No. shares '28

US$6.87

Share Price '28

US$6.87 Share Price '28

Discounted to 2025 @ 11.74% p.a.

US$4.93

Fair Value '25